Lifecore Biomedical
LFCR
101 hedge funds and large institutions have $302M invested in Lifecore Biomedical in 2014 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 35 increasing their positions, 39 reducing their positions, and 6 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
50% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 6
14% more capital invested
Capital invested by funds: $265M → $302M (+$36.7M)
3% more funds holding
Funds holding: 98 → 101 (+3)
10% less repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 39
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $275K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RA
Royce & Associates
New York
|
+$3.59M |
| 2 |
SCM
Summit Capital Management
Seattle,
Washington
|
+$3.48M |
| 3 |
Boston Partners
Boston,
Massachusetts
|
+$1.66M |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$1.54M |
| 5 |
PI
Putnam Investments
Boston,
Massachusetts
|
+$1.46M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OCG
Opus Capital Group
Cincinnati,
Ohio
|
-$1.85M |
| 2 |
Principal Financial Group
Des Moines,
Iowa
|
-$1.67M |
| 3 |
Renaissance Technologies
New York
|
-$1.66M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$1.61M |
| 5 |
Public Employees Retirement Association of Colorado
Denver,
Colorado
|
-$913K |
LFCR Hedge Fund Activity: Q2 2014 in Review
101 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in Lifecore Biomedical (LFCR) for Q2 2014, worth a combined $302M — up 14% from $265M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new LFCR positions and 6 closed out — a net gain of 3 holders — while 35 added to existing stakes and 39 trimmed.
The largest buyer was Royce & Associates, adding an estimated $3.59M. The largest seller was Opus Capital Group, cutting an estimated $1.85M.
- 101 institutional investors held Lifecore Biomedical (LFCR) as of Q2 2014, up from 98 in Q1 2014.
- Funds reported $302M of Lifecore Biomedical stock for Q2 2014, up 14% quarter-over-quarter.
- 9 funds opened new Lifecore Biomedical positions in Q2 2014 and 6 closed out, a net change of +3 holders.
- The largest Lifecore Biomedical buyer in Q2 2014 was Royce & Associates, an estimated $3.59M added.
- The largest Lifecore Biomedical seller in Q2 2014 was Opus Capital Group, an estimated $1.85M sold.
Based on aggregated 13F filings for Q2 2014.